Document is current
Any future updates will be listed below
-
Authors
Sun, Jennifer
Park, Chaelee https://orcid.org/0000-0002-3909-0096
Guenthner, Nicole
Gurley, Shannon
Zhang, Luna
Lubben, Berit
Adebayo, Ola
Bash, Hannah
Chen, Yixuan https://orcid.org/0000-0001-7496-9648
Maksimos, Mina
Muz, Barbara
Azab, Abdel Kareem https://orcid.org/0000-0002-1836-2785
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02663518 at ClinicalTrials.govnct03530683 at ClinicalTrials.govDocuments that mention this clinical trial
Novel treatments in B cell non-Hodgkin’s lymphomas
https://doi.org/10.1136/bmj-2020-063439
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
CD47/SIRPα axis: bridging innate and adaptive immunity
https://doi.org/10.1136/jitc-2022-004589
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
nct04445701 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
nct03512340 at ClinicalTrials.govDocuments that mention this clinical trial
260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics
https://doi.org/10.1136/jitc-2021-sitc2021.260
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
https://doi.org/10.1136/jitc-2020-sitc2020.0215
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
nct01025206 at ClinicalTrials.govDocuments that mention this clinical trial
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
https://doi.org/10.1136/jitc-2019-000413
Novel treatments in B cell non-Hodgkin’s lymphomas
https://doi.org/10.1136/bmj-2020-063439
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
nct01838369 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
nct02756728 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
Documents that mention this clinical trial
Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
https://doi.org/10.1136/jitc-2021-003975
-
Funding
Funding for this research was provided by:
National Cancer Institute (U54CA199092)
- License Information
